Results of the Galenica Group for 2014
Tuesday, 10 March 2015, ↓ directly to download
Double-digit growth in earnings per share on a comparable basis:
Galenica increases net profit for the 19th consecutive year.
The Galenica Group increased net profit for the 19th consecutive year in 2014.
On a comparable basis excluding one-time effects, net profit increased by 5.3% to CHF 312.0 million before deduction of minority interests, and by 10.4% to
CHF 284.5 million after deduction of minority interests. Consolidated earnings before interest, taxes, depreciation and amortisation (EBITDA) rose by 0.8% to CHF 446.8 million, and earnings before interest and taxes (EBIT) by 0.7% to
CHF 370.2 million.
Galenica management has set itself the target of achieving at least the same level of profit in 2015 as in the previous year, both before and after deduction of minority interests and calculated on a comparable exchange rate basis to 2014 and considering all current projects. Should the average exchange rate of February 2015 prevail for the remainder of the year, this would negatively affect net profit versus 2014 by less than 10%.
The Board of Directors will recommend a dividend of CHF 15.00 per registered share (previous year: CHF 14.00) to the Annual General Meeting on 7 May 2015.
Vifor Pharma increased net sales by 6.6% to CHF 706.2 million. Earnings before interest and taxes (EBIT) decreased by 1.6% to CHF 265.0 million, almost offsetting the planned decline in other operating income.
In 2014, the USA became the strongest sales market for Ferinject®/Injectafer®, with market sales rising by an average of more than 10% every month. Based on the IMS data, global market sales in 2014 totalled approximately CHF 265 million, representing an increase of 42%.
The novel phosphate binder Velphoro® was launched in the USA in March and in initial European countries in the fourth quarter.
The highest priorities for 2015 are: continual expansion of iron replacement products; successful launch of Velphoro® in additional countries; and Business unit development through internal growth, new partnerships and targeted acquisitions.
Galenica Santé asserted itself very well in a stagnating market through new services and the acquisition of new customers. The Business unit achieved higher sales year-on-year of CHF 2,781.9 million (+0.6%), thereby gaining market share. Operating income (EBIT) was increased by 3.6% to CHF 102.9 million.
The activities of Vifor Pharma Consumer Health will be transferred to the Galenica Santé Business unit as a fourth Consumer Health Business sector by mid-2015. At the same time, top priorities for 2015 remain the successful implementation of ongoing strategic projects and continuing exploitation of potential synergies.
(Click on the image to enlarge the picture.)
Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).
Tuesday, 1 December 2015
Wednesday, 30 September 2015
Tuesday, 11 August 2015
Tuesday, 11 August 2015
Head of Corporate Communications
Head Investor Relations